Tiburio is a clinical stage biopharmaceutical company dedicated to advancing novel treatments for rare neuroendocrine tumors and rare endocrine diseases where there is significant patient need. The company's pipeline consists of two clinical stage compounds, TBR-760 for the treatment of non-functioning pituitary adenoma (NFPA) and TBR-065 for additional rare endocrine diseases.